There was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and ...

"Based on our research, there is promising potential for GLP-1RAs and SGLT2is to be considered for Alzheimer's disease prevention in the future. As use of these drugs continues to expand ...

Orforglibron, a pill form of GLP-1 weight loss ... diabetes or heart disease, while about 4 in 10 say they took them primarily to lose weight. About 40% of adults in the U.S. have obesity ...

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors demonstrated lower risks of developing Alzheimer disease ...

A U.S. senator said a GLP-1 drug changed his life — and now he’s calling for ... potentially slowing or preventing conditions ...

Idiopathic REM sleep behavior ... Clinical Trial Tests Novel Stem-Cell Treatment for Parkinson's Disease Mar. 9, 2025 — A recently launched Phase 1 clinical trial is examining the safety and ...

With around one million people living with Parkinson’s disease in the U.S. — and 90,000 ... to treat advanced Parkinson’s. In the phase 1 trial, the researchers used donated stem cells ...

One in eight adults have taken a glucagon-like peptide 1 (GLP-1) agonist to lose weight or to treat a comorbidity like type 2 diabetes or cardiovascular disease ... It’s important to fully ...

“Based on our research, there is promising potential for GLP-1RAs and SGLT2is to be considered for Alzheimer’s disease prevention in the future. As use of these drugs continues to ...